Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), will host a business update conference call on August 13, 2025, at 8:30 AM ET.
The call will feature CEO Lishan Aklog discussing business operations and growth strategy, while CFO Dennis McGrath will present Q2 2025 financial results. Investors can access the webcast through luciddx.com or join by phone using specific dial-in numbers for U.S. and international callers.
Lucid Diagnostics (Nasdaq: LUCD), un'azienda di diagnostica medica per la prevenzione del cancro in fase commerciale e controllata da PAVmed (Nasdaq: PAVM), terrà una conference call di aggiornamento aziendale il 13 agosto 2025 alle 8:30 AM ET.
Durante la chiamata, l'amministratore delegato Lishan Aklog parlerà delle operazioni aziendali e della strategia di crescita, mentre il CFO Dennis McGrath presenterà i risultati finanziari del secondo trimestre 2025. Gli investitori potranno seguire la diretta streaming su luciddx.com o partecipare telefonicamente utilizzando i numeri dedicati per chiamate dagli Stati Uniti e dall'estero.
Lucid Diagnostics (Nasdaq: LUCD), una empresa de diagnóstico médico para la prevención del cáncer en etapa comercial y subsidiaria de PAVmed (Nasdaq: PAVM), realizará una llamada de actualización empresarial el 13 de agosto de 2025 a las 8:30 AM ET.
La llamada contará con la participación del CEO Lishan Aklog, quien hablará sobre las operaciones comerciales y la estrategia de crecimiento, mientras que el CFO Dennis McGrath presentará los resultados financieros del segundo trimestre de 2025. Los inversores podrán acceder a la transmisión en vivo a través de luciddx.com o unirse por teléfono utilizando números específicos para llamadas desde EE.UU. e internacionales.
Lucid Diagnostics (나스닥: LUCD)는 상업 단계의 암 예방 의료 진단 회사로, PAVmed (나스닥: PAVM)의 자회사입니다. 2025년 8월 13일 오전 8시 30분(동부시간)에 사업 업데이트 컨퍼런스 콜을 개최합니다.
이번 콜에서는 CEO Lishan Aklog가 사업 운영 및 성장 전략에 대해 이야기하고, CFO Dennis McGrath가 2025년 2분기 재무 실적을 발표할 예정입니다. 투자자들은 luciddx.com을 통해 웹캐스트에 접속하거나 미국 및 국제 전화를 위한 별도의 전화번호를 이용해 전화로 참여할 수 있습니다.
Lucid Diagnostics (Nasdaq : LUCD), une société de diagnostic médical en phase commerciale spécialisée dans la prévention du cancer et filiale de PAVmed (Nasdaq : PAVM), organisera une conférence téléphonique de mise à jour commerciale le 13 août 2025 à 8h30 ET.
Lors de cet appel, le PDG Lishan Aklog présentera les opérations commerciales et la stratégie de croissance, tandis que le directeur financier Dennis McGrath exposera les résultats financiers du deuxième trimestre 2025. Les investisseurs pourront accéder à la diffusion en direct via luciddx.com ou participer par téléphone en utilisant des numéros d'appel spécifiques pour les États-Unis et les appels internationaux.
Lucid Diagnostics (Nasdaq: LUCD), ein Unternehmen im Bereich der medizinischen Krebspräventionsdiagnostik in der kommerziellen Phase und Tochtergesellschaft von PAVmed (Nasdaq: PAVM), wird am 13. August 2025 um 8:30 Uhr ET eine Telefonkonferenz zur Unternehmensaktualisierung abhalten.
Während des Calls wird CEO Lishan Aklog über Geschäftsabläufe und Wachstumsstrategien sprechen, während CFO Dennis McGrath die Finanzergebnisse für das zweite Quartal 2025 präsentieren wird. Investoren können den Webcast über luciddx.com verfolgen oder sich telefonisch über spezielle Einwahlnummern für US-amerikanische und internationale Teilnehmer zuschalten.
- None.
- None.
Conference Call and Webcast at 8:30 AM Eastern Time
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone,
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-august-13-2025-302516614.html
SOURCE Lucid Diagnostics
FAQ
When is Lucid Diagnostics (LUCD) Q2 2025 earnings call scheduled?
How can investors access the Lucid Diagnostics (LUCD) conference call?
Who will be presenting at the Lucid Diagnostics (LUCD) Q2 2025 earnings call?
How long will the Lucid Diagnostics (LUCD) earnings call replay be available?
